Want to see BTMD full AI Analyst Report?
BTMD Stock Chart & Stats
$2.28
$0.06(2.63%)
At close: 4:00 PM EDT
$2.28
$0.06(2.63%)
Day’s Range― - ―
52-Week Range$1.27 - $3.62
Previous CloseN/A
Volume52.46K
Average Volume (3M)315.30K
Market Cap
$57.84M
Enterprise Value$179.17
Total Cash (Recent Filing)$11.17M
Total Debt (Recent Filing)$128.64M
Price to Earnings (P/E)9.6
Beta1.23
Next Earnings
Nov 10, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding28,677,590
10 Day Avg. Volume335,797
30 Day Avg. Volume315,298
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.39
Price to Sales (P/S)0.42
P/FCF Ratio2.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.00Price Target Upside-12.28% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.12
Revenue Forecast (FY)$180.71M
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationPositive operating and free cash flow show the platform can convert operations into liquidity. Although recent momentum softened, sustained cash generation provides funding for provider support, product development and debt obligations.
Supplements GrowthSupplements growth diversifies revenue beyond hormone procedures and benefits from e-commerce and clinical recommendations. Continued expansion could improve recurring patient engagement and reduce dependence on the pellet business.
Supply NormalizationRestored supply and greater internal manufacturing capacity should reduce reliance on higher-cost third-party pellets. Over time, this can support product availability, improve gross margins and strengthen execution across the provider network.
Bears Say
Balance-Sheet RiskNegative equity combined with sizable debt limits financial flexibility and raises vulnerability to operating setbacks. The balance sheet may constrain investment in growth initiatives and increase refinancing or liquidity pressure during downturns.
Lower Earnings OutlookMaterial guidance reductions indicate weaker demand, execution or cost absorption than previously expected. The lower outlook reduces confidence in medium-term earnings recovery and suggests that margin rebuilding may take longer.
Clinic AttritionPersistent provider attrition threatens the clinic network that drives recurring procedure and product orders. Slower new-clinic productivity compounds the issue, potentially limiting network expansion and delaying a durable return to procedure revenue growth.
biote News
BTMD FAQ
What was biote’s price range in the past 12 months?
biote lowest stock price was $1.27 and its highest was $3.62 in the past 12 months.
What is biote’s market cap?
biote’s market cap is $57.84M.
When is biote’s upcoming earnings report date?
biote’s upcoming earnings report date is Nov 10, 2026 which is in 78 days.
How were biote’s earnings last quarter?
biote released its earnings results on Aug 05, 2026. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of $0.027 by -$0.257.
Is biote overvalued?
According to Wall Street analysts biote’s price is currently Overvalued.
Does biote pay dividends?
biote does not currently pay dividends.
What is biote’s EPS estimate?
biote’s EPS estimate is >-0.01.
How many shares outstanding does biote have?
biote has 28,677,590 shares outstanding.
What happened to biote’s price movement after its last earnings report?
biote reported an EPS of -$0.23 in its last earnings report, missing expectations of $0.027. Following the earnings report the stock price went down -27.876%.
Which hedge fund is a major shareholder of biote?
Currently, no hedge funds are holding shares in BTMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
biote Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.00 (-12.28% Downside)
$2.00 (-12.28% Downside)
Blogger Sentiment
Bullish
BTMD Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $202.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Company Description
biote
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
BTMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call contained meaningful operational progress — restored supply, normalized inventory, a stronger commercial team, positive adjusted EBITDA, and growing supplements revenue — but these positives were outweighed by significant near-term financial headwinds: total revenue fell 9.5%, procedure revenue declined 13.9% (with a $3.3M recall impact), gross margin compressed by 6.2 percentage points, SG&A rose materially (driven by legal costs), the company swung to a GAAP net loss of $7.4M, and management cut full-year guidance (revenue and adjusted EBITDA). While management expects sequential improvement in H2 2026, the magnitude of the year-over-year deterioration and the guidance reductions dominate the call's tone.View all BTMD earnings summariesBTMD Stock 12 Month Forecast
Average Price Target
$2.00
▼(-12.28% Downside)
Technical Analysis
Concord Medical Services
―
Joint
―
Cryo-Cell International
―
DocGo
―
P3 Health Partners
―
Ownership Overview
9.99% Insiders
9.82% Mutual Funds
24.83% Other Institutional Investors
50.44% Public Companies and
Individual Investors